Ignite Creation Date:
2024-05-06 @ 7:26 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06016738
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2023-08-17
Brief Title:
OP-1250 Palazestrant vs Standard of Care for the Treatment of ERHER2- Advanced Breast Cancer
Sponsor:
Olema Pharmaceuticals Inc
Organization:
Olema Pharmaceuticals Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
| Advanced Breast Cancer |
| Metastatic Breast Cancer |
| ER Positive Breast Cancer |
| HER2 Negative Breast Carcinoma |
Keywords: